(2S)-2-(cyclopropylmethyl)-N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]heptanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-(cyclopropylmethyl)-N-[(3S)-1-methyl-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]heptanamide
• 化学式: C₂₇H₃₃N₃O₂
• 分子量: 431.6
• InChiKey: YCKMBYNOWOGNGJ-SQJMNOBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  61.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted lactams as inhibitors of A beta protein production
  申请人：——

  公开号：US20020025955A1

  公开（公告）日：2002-02-28

  This invention relates to novel lactams of Formula (I): 1 having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺化合物（I）的公式，以及它们的制药组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制A&bgr;-肽的产生，从而防止淀粉样蛋白质的神经沉积形成。更具体地，本发明涉及与&bgr;-淀粉样蛋白产生相关的神经疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• Substituted lactams as inhibitors of Abeta protein production
  申请人：——

  公开号：US20040138201A1

  公开（公告）日：2004-07-15

  This invention relates to novel lactams of Formula (I): 1 having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺化合物，其化学式为(I)：1，以及它们的制药组合物和使用方法。这些新的化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ肽的产生，从而防止淀粉样蛋白神经沉积物的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。
• Substituted lactams as inhibitors of abeta protein production
  申请人：Han Qi

  公开号：US20080221087A1

  公开（公告）日：2008-09-11

  This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响特性的新型内酰胺化合物，其化学式为（I）。本发明还涉及这些新型化合物的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地，抑制Aβ肽的产生，从而防止淀粉样蛋白的神经沉积物的形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。
• SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION
  申请人：HAN Qi

  公开号：US20100009966A1

  公开（公告）日：2010-01-14

  This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺化合物（I）的制备方法，以及它们的制药组合物和使用方法。这些新化合物可以抑制淀粉样前体蛋白的加工，更具体地，抑制Aβ-肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病（如阿尔茨海默病和唐氏综合症）的治疗方法。
• SUBSTITUTED LACTAMS AS INHIBITORS OF A BETA PROTEIN PRODUCTION
  申请人：Han Qi

  公开号：US20100069373A1

  公开（公告）日：2010-03-18

  This invention relates to novel lactams of Formula (I): having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及公式（I）的新型内酰胺，具有药物和生物影响性质，其药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，如阿尔茨海默病和唐氏综合症。